Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462465 | 1.00 | GPR119 (0.38) | GPR119SCN3APSEN1PSEN2APH1B | |
| SCHEMBL14815434 | 0.91 | KDM4E (0.41) | GPR119SCN3ATRPV4LMNA | |
| SCHEMBL14816147 | 0.91 | KDM4E (0.41) | GPR119SCN3ATRPV4LMNA | |
| SCHEMBL14815581 | 0.91 | KDM4E (0.41) | GPR119SCN3ATRPV4LMNA | |
| SCHEMBL14815749 | 0.89 | POLB (0.43) | GPR119LMNA | |
| SCHEMBL15462522 | 0.89 | POLB (0.43) | GPR119LMNA | |
| SCHEMBL14815885 | 0.88 | KCNH2 (0.40) | GPR119GCKLMNA | |
| SCHEMBL14815402 | 0.88 | MAPT (0.39) | LMNA | |
| SCHEMBL15462473 | 0.88 | MAPT (0.39) | LMNA | |
| SCHEMBL14815583 | 0.88 | SCN3A (0.38) | GPR119SCN3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | GPR119 2105/4885SCN3A 116/4885PSEN1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.